HAINAN WEI-KANG PHARMACEUTICAL (QIANSHAN) COMPANY LIMITED
发明人:
Liuyi Wang,Jincan Wang,Dingwen Zhou
申请号：
US14411848
公开号：
US20160263094A1
申请日:
2014.06.11
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The invention provides pantoprazole sodium composition lyophilized powder for injection, and relates to the technical field of medicines and manufacturing of the medicines. The pantoprazole sodium composition lyophilized powder for injection comprises the following raw material ingredients in parts by weight: 7.24-9.08 parts of pantoprazole sodium, 4.34-5.45 parts of chitosan nanoparticles and 85.25-89.11 parts of water for injection. The invention has the following advantages: 1) a composition comprising pantoprazole sodium and chitosan nanoparticles according to a ratio of 1:0.6 has a stronger effect of inhibiting an H+-K+ATPase； 2) the using amount of pantoprazole sodium can be clinically reduced, the adverse reactions of pantoprazole sodium are reduced, and 20 mg of pantoprazole sodium containing the chitosan nanoparticles has the same effect of inhibiting secretion of gastric acid as 30 mg of pantoprazole sodium without the chitosan nanoparticles； 3) the water solubility of the medicament is improved, and the good stability of the medicament is simultaneously ensured； 4) the medicament-carrying nanoparticles can change a membrane operation mechanism, increase the permeability of the medicament across a biological membrane and be conductive to realize an efficacy of the medicament in cells； and 5) the chitosan nanoparticles can replace mannitol to serve as a lyophilized skeleton agent of the lyophilized powder, thereby eliminating an active effect of mannitol on a human body.
